Aa
new Cuban vaccine against chronic hepatitis
A new Cuban vaccine against chronic hepatitis B, created by the Genetic Engineering and Biotechnology Center, or CIGB, is currently undergoing clinical trials in eight countries, organized with the collaboration of the French company Abivax, official media reported Tuesday.
Named HeberNasvac, this new product is injected via nasal passages or subcutaneously, and has proved to be "safer and more effective" than all other existing medications available for this virus, the official daily Granma said on its front page.
Clinical trials of HeberNasvac are being made with a sample of 230 patients in 50 clinics in Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, the Philippines and Thailand.
The protocol for the medical evaluation was designed by leading experts contracted by Abivax along with Cuban scientists, according to officials at the CIGB, who confirmed the satisfactory progress of the trials in Asia, one of the regions most affected by the virus.
According to figures of the World Health Organization, or WHO, close to 1 million deaths occur every year related to the hepatitis B virus, one of the chief causes of cancer of the liver, cirrhosis of the liver and other complications like ascites, varicose veins of the esophagus and splenomegaly.
A second clinical study of the new vaccine, still in the phase of recruiting the sample of patients, will take place at 13 medical centers in Cuba and will benefit 160 patients on the island, the official news agency Prensa Latina said.
In Cuba, where projects related to creating new medications have several times won the National Prize of the Academy of Sciences, use of the vaccine is expected to begin in 2016, after being approved for inclusion in the medical register by the Cuban Center for State Control of Medications, Equipment and Medical Devices.
In November 2014, Cuba announced that preventive vaccines against cholera, pneumococcus and hepatitis B were being prepared for registration and application this year. All were described as highly innovative, safe and effective products by medical authorities on the island. EFE
Named HeberNasvac, this new product is injected via nasal passages or subcutaneously, and has proved to be "safer and more effective" than all other existing medications available for this virus, the official daily Granma said on its front page.
Clinical trials of HeberNasvac are being made with a sample of 230 patients in 50 clinics in Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, the Philippines and Thailand.
The protocol for the medical evaluation was designed by leading experts contracted by Abivax along with Cuban scientists, according to officials at the CIGB, who confirmed the satisfactory progress of the trials in Asia, one of the regions most affected by the virus.
According to figures of the World Health Organization, or WHO, close to 1 million deaths occur every year related to the hepatitis B virus, one of the chief causes of cancer of the liver, cirrhosis of the liver and other complications like ascites, varicose veins of the esophagus and splenomegaly.
A second clinical study of the new vaccine, still in the phase of recruiting the sample of patients, will take place at 13 medical centers in Cuba and will benefit 160 patients on the island, the official news agency Prensa Latina said.
In Cuba, where projects related to creating new medications have several times won the National Prize of the Academy of Sciences, use of the vaccine is expected to begin in 2016, after being approved for inclusion in the medical register by the Cuban Center for State Control of Medications, Equipment and Medical Devices.
In November 2014, Cuba announced that preventive vaccines against cholera, pneumococcus and hepatitis B were being prepared for registration and application this year. All were described as highly innovative, safe and effective products by medical authorities on the island. EFE
It has not much enthusiasm amongst hbv ppl since it another endless shop. It will be a waste if it can't clear virus on nuc combo.
this vaccine is designed to control not cure hbv. i though they were talking about a "fuctional cure". it is Nucs like vaccine.
Hi is Abivax being made to cure HBV? or is it made to treat it with nucs for us to manage it for the long term?
Second one will be better, but since the vaccine comes first most of ppl will certainly go for it. It wud be better to wait first and c some results then try it(vaccine)
in cuba and south america will be cheaper, hcv drugs prices are unreal for those markets
i think a good combo will be peg+vaccine or rep9acplus vaccine
i think a good combo will be peg+vaccine or rep9acplus vaccine
Yes it is for cure of hcv recently invented. Same company has started work on hbv cure and that certainly not gonna cost less than this. Hope indian genres provide that at lesser price. But it's a long time to pass from now.
Jatashankar,
Is it for cure? I wouldn't spend this much money for cure. Rather I wait for few years till price reduces if at all it's for cure :)
Is it for cure? I wouldn't spend this much money for cure. Rather I wait for few years till price reduces if at all it's for cure :)
Yes by late 2016. For others still long wait. Gilead science is on for hbv after hcv. Sovaldi for hcv cost $84000 for therapy so be ready to loosen ur pockets similarly in future
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
